Moreover, these results suggest that, in combination with MRTX849, targeting both the EGFR and HER2/3 signaling pathways has greater anti-tumor activity compared to targeting EGFR (with erlotinib) alone. This evidence concerns the gene ERBB2 and neoplasm.